Validamycin B

CAS : 102583-47-1

Ref. 3D-CEA58347

Informations sur le produit

• Nom: Validamycin B
• Synonymes: Antibiotic T 7545B, 1,5-Dideoxy-4-O-β-D-glucopyranosyl-5-(hydroxymethyl)-1-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-D-chiro-inositol, D-chiro-Inositol, 1,5-dideoxy-4-O-β-D-glucopyranosyl-5-(hydroxymethyl)-1-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-, D-chiro-Inositol, 1,5-dideoxy-4-O-β-D-glucopyranosyl-5-(hydroxymethyl)-1-[[4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-, [1S-(1α,4α,5β,6α)]-

Description

Validamycin B is a medicinal compound that has been found to have potential anticancer properties. This human analog acts as an inhibitor of certain proteins involved in the cell cycle, leading to apoptosis or programmed cell death in cancer cells. Validamycin B has been shown to be effective against various types of cancer, including lung, colon, and breast cancer. It inhibits the activity of kinases that are important for tumor growth and proliferation. The compound is excreted through urine and can be used as a diagnostic tool for detecting cancer. Validamycin B is a promising candidate for the development of novel anticancer drugs.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 513.5 g/mol
• Formule: C₂₀H₃₅NO₁₄
• Degré de pureté: Min. 95%